메뉴 건너뛰기




Volumn 187, Issue 6, 2012, Pages 2074-2081

The finnprostate study VII: Intermittent versus continuous androgen deprivation in patients with advanced prostate cancer

Author keywords

androgens; prostatic neoplasms; testosterone

Indexed keywords

ALKALINE PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

EID: 84861100861     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.01.122     Document Type: Article
Times cited : (63)

References (23)
  • 1
    • 84928580276 scopus 로고
    • Studies on prostatic cancer: I the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
    • C. Huggins, C.V. Hodges Studies on prostatic cancer: I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293
    • (1941) Cancer Res , vol.1 , pp. 293
    • Huggins, C.1    Hodges, C.V.2
  • 2
    • 67649678763 scopus 로고    scopus 로고
    • Complications of androgen deprivation therapy in prostate cancer
    • A. Schwandt, J.A. Garcia Complications of androgen deprivation therapy in prostate cancer Curr Opin Urol 19 2009 322
    • (2009) Curr Opin Urol , vol.19 , pp. 322
    • Schwandt, A.1    Garcia, J.A.2
  • 3
    • 66649136169 scopus 로고    scopus 로고
    • Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer
    • L.G. Taylor, S.E. Canfield, X.L. Du Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer Cancer 115 2009 2388
    • (2009) Cancer , vol.115 , pp. 2388
    • Taylor, L.G.1    Canfield, S.E.2    Du, X.L.3
  • 4
    • 70449523110 scopus 로고    scopus 로고
    • Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature
    • P.A. Abrahamsson Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature Eur Urol 57 2010 49
    • (2010) Eur Urol , vol.57 , pp. 49
    • Abrahamsson, P.A.1
  • 5
    • 48849104783 scopus 로고    scopus 로고
    • Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: Interim analysis of prognostic markers affecting initial response to androgen deprivation
    • A.J. Salonen, J. Viitanen, S. Lundstedt Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation J Urol 180 2008 915
    • (2008) J Urol , vol.180 , pp. 915
    • Salonen, A.J.1    Viitanen, J.2    Lundstedt, S.3
  • 6
    • 0142228727 scopus 로고    scopus 로고
    • Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study
    • W. Albrecht, L. Collette, C. Fava Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study Eur Urol 44 2003 505
    • (2003) Eur Urol , vol.44 , pp. 505
    • Albrecht, W.1    Collette, L.2    Fava, C.3
  • 7
    • 12244271448 scopus 로고    scopus 로고
    • A 10-year clinical experience with intermittent hormonal therapy for prostate cancer
    • D. Prapotnich, K. Fizazi, B. Escudier A 10-year clinical experience with intermittent hormonal therapy for prostate cancer Eur Urol 43 2003 233
    • (2003) Eur Urol , vol.43 , pp. 233
    • Prapotnich, D.1    Fizazi, K.2    Escudier, B.3
  • 8
    • 41149171703 scopus 로고    scopus 로고
    • Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)
    • U.E. Studer, L. Collette, P. Whelan Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol 53 2008 941
    • (2008) Eur Urol , vol.53 , pp. 941
    • Studer, U.E.1    Collette, L.2    Whelan, P.3
  • 9
    • 0032991677 scopus 로고    scopus 로고
    • Intermittent complete androgen blockade in metastatic prostate cancer
    • J. Rambeaud Intermittent complete androgen blockade in metastatic prostate cancer Eur Urol 35 1999 32
    • (1999) Eur Urol , vol.35 , pp. 32
    • Rambeaud, J.1
  • 10
    • 53749103325 scopus 로고    scopus 로고
    • Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
    • B. Seruga, I.F. Tannock Intermittent androgen blockade should be regarded as standard therapy in prostate cancer Nat Clin Pract Oncol 5 2008 574
    • (2008) Nat Clin Pract Oncol , vol.5 , pp. 574
    • Seruga, B.1    Tannock, I.F.2
  • 11
    • 34548443017 scopus 로고    scopus 로고
    • The role of intermittent androgen deprivation in prostate cancer
    • L. Boccon-Gibod, P. Hammerer, S. Madersbacher The role of intermittent androgen deprivation in prostate cancer BJU Int 100 2007 738
    • (2007) BJU Int , vol.100 , pp. 738
    • Boccon-Gibod, L.1    Hammerer, P.2    Madersbacher, S.3
  • 12
    • 77957315589 scopus 로고    scopus 로고
    • Intermittent androgen deprivation therapy: Redefining the standard of care?
    • N.D. Shore, E.D. Crawford Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol 12 2010 1
    • (2010) Rev Urol , vol.12 , pp. 1
    • Shore, N.D.1    Crawford, E.D.2
  • 13
    • 0000368040 scopus 로고    scopus 로고
    • Intermittent androgen suppression for prostate cancer: Rationale and clinical experience
    • M. Gleave, S.L. Goldenberg, N. Bruchovsky Intermittent androgen suppression for prostate cancer: rationale and clinical experience Prostate Cancer Prostatic Dis 1 1998 289
    • (1998) Prostate Cancer Prostatic Dis , vol.1 , pp. 289
    • Gleave, M.1    Goldenberg, S.L.2    Bruchovsky, N.3
  • 14
    • 0034903581 scopus 로고    scopus 로고
    • Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy
    • G.D. Grossfeld, E.J. Small, D.P. Lubeck Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy Urology 58 2001 56
    • (2001) Urology , vol.58 , pp. 56
    • Grossfeld, G.D.1    Small, E.J.2    Lubeck, D.P.3
  • 15
    • 65049090443 scopus 로고    scopus 로고
    • Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group
    • F.E. Calais da Silva, A.V. Bono, P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269
    • (2009) Eur Urol , vol.55 , pp. 1269
    • Calais Da Silva, F.E.1    Bono, A.V.2    Whelan, P.3
  • 16
    • 33748465540 scopus 로고    scopus 로고
    • Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162)
    • M. Hussain, C.M. Tangen, C. Higano Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 2006 3984
    • (2006) J Clin Oncol , vol.24 , pp. 3984
    • Hussain, M.1    Tangen, C.M.2    Higano, C.3
  • 17
    • 70349485852 scopus 로고    scopus 로고
    • A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: Oncological results
    • D. Prapotnich, X. Cathelineau, F. Rozet A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results World J Urol 27 2009 627
    • (2009) World J Urol , vol.27 , pp. 627
    • Prapotnich, D.1    Cathelineau, X.2    Rozet, F.3
  • 18
    • 12444317207 scopus 로고    scopus 로고
    • Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: Results of a prospective randomized multicenter trial
    • J. de Leval, P. Boca, E. Yousef Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial Clin Prostate Cancer 1 2002 163
    • (2002) Clin Prostate Cancer , vol.1 , pp. 163
    • De Leval, J.1    Boca, P.2    Yousef, E.3
  • 19
    • 0033762705 scopus 로고    scopus 로고
    • A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy
    • R.J. Nejat, H.H. Rashid, E. Bagiella A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy J Urol 164 2000 1891
    • (2000) J Urol , vol.164 , pp. 1891
    • Nejat, R.J.1    Rashid, H.H.2    Bagiella, E.3
  • 20
    • 17144414951 scopus 로고    scopus 로고
    • A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy
    • J.L. Gulley, W.D. Figg, S.M. Steinberg A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy J Urol 173 2005 1567
    • (2005) J Urol , vol.173 , pp. 1567
    • Gulley, J.L.1    Figg, W.D.2    Steinberg, S.M.3
  • 21
    • 33746387985 scopus 로고    scopus 로고
    • Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer
    • N.A. Spry, L. Kristjanson, B. Hooton Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer Eur J Cancer 42 2006 1083
    • (2006) Eur J Cancer , vol.42 , pp. 1083
    • Spry, N.A.1    Kristjanson, L.2    Hooton, B.3
  • 22
    • 45849110316 scopus 로고    scopus 로고
    • Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: A randomised study
    • J. Irani, O. Celhay, J. Hubert Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study Eur Urol 54 2008 382
    • (2008) Eur Urol , vol.54 , pp. 382
    • Irani, J.1    Celhay, O.2    Hubert, J.3
  • 23
    • 80053201964 scopus 로고    scopus 로고
    • The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation
    • D. Keizman, P. Huang, E.S. Antonarakis The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation Prostate 71 2011 1608
    • (2011) Prostate , vol.71 , pp. 1608
    • Keizman, D.1    Huang, P.2    Antonarakis, E.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.